Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from GRI Bio ( (GRI) ).
On January 28, 2026, GRI Bio reported additional positive data from its recently completed Phase 2a clinical trial of GRI-0621 in idiopathic pulmonary fibrosis, showing that RNA-sequencing gene expression analysis revealed significant modulation of genes linked to lung injury, myofibroblast activation, extracellular matrix deposition, fibrosis progression, and alveolar repair compared with placebo. The new molecular findings align with earlier biomarker and functional data indicating reduced neutrophil activity, lower pro-fibrotic cytokine levels, increased collagen degradation, and signals consistent with lung repair and regeneration, suggesting that GRI-0621 may act as a disease-modifying therapy that supports true lung tissue regeneration rather than merely slowing decline; these effects were observed alongside a favorable safety profile and secondary endpoint signals, including a higher proportion of patients with no decline in forced vital capacity at 12 weeks versus standard of care, underscoring the candidate’s potential differentiation within the IPF treatment landscape.
The most recent analyst rating on (GRI) stock is a Sell with a $0.22 price target. To see the full list of analyst forecasts on GRI Bio stock, see the GRI Stock Forecast page.
Spark’s Take on GRI Stock
According to Spark, TipRanks’ AI Analyst, GRI is a Neutral.
The score is held down primarily by weak financial performance (large operating losses and continued cash burn) and bearish technicals (price below key moving averages with negative MACD). Corporate events provide a partial offset via positive Phase 2a data and recent financing, but valuation support is limited by negative earnings and no dividend yield data.
To see Spark’s full report on GRI stock, click here.
More about GRI Bio
GRI Bio, Inc. is a clinical-stage biopharmaceutical company developing immune cell modulators targeting Natural Killer T (NKT) cells to treat inflammatory, fibrotic and autoimmune diseases. Its lead program, GRI-0621, an oral RARβγ agonist that inhibits key immune cells such as invariant NKT cells, is being developed for idiopathic pulmonary fibrosis, while the company is also advancing a pipeline of diverse NKT agonists for systemic lupus erythematosus, supported by a library of more than 500 proprietary compounds.
Average Trading Volume: 97,691
Technical Sentiment Signal: Sell
Current Market Cap: $2.98M
See more insights into GRI stock on TipRanks’ Stock Analysis page.